Lyzm cre

C57BL/6 mice were obtained from Joint Ventures Sipper BK Experimental Animal (Shanghai, China). Rig-I^f/f mouse was constructed by ViewSolid Biotech (Beijing, China) using CRISPR/Cas9 techniques as previously described [19 (link)] and then mated with Alb-Cre transgenic mouse (003574), obtained from The Jackson Laboratory (Bar Harbor, ME), to generate hepatocyte-specific deficiency. Jmjd4^f/f mouse, Rig-I K18A+K146A mutant mouse, and K18M+K146M mutant mouse were constructed by Cyagen (Suzhou, China) also using CRISPR/Cas9 strategy. IL-6^−/− (002650), IL-6ra^f/f (012944), and LyzM-Cre (004781) mice were obtained from The Jackson Laboratory. ApoE^−/− mouse (T001458) was from GemPharmatech (Nanjing, China). Mouse genotyping was done by PCR analysis on genomic DNA extracted from tails as previously described [20 (link)]. All animals were housed in a specific pathogen-free facility and maintained in a standard temperature- and light-controlled animal facility. All animal experiments were undertaken in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals, with the approval of the Scientific Investigation Board of Second Military Medical University, Shanghai, China.

Mice that express Cre recombinase under control of the lysozyme M promoter (LyzM⁺.Cre) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). FOXO1^L/L mice were generously provided by Dr. Ronald DePinho (University of Texas MD Anderson Cancer Center, Houston, TX, USA) (21 (link)). FOXO1^L/L mice were bred with LyzM.Cre mice to generate experimental mice (LyzM.Cre⁺FOXO1^L/L) and the control littermates (LyzM.Cre⁻FOXO1^L/L) as described (20 (link)). Genotypes were determined by PCR using primers specific for LyzM.Cre (5′-ATCCGAAAAGAAAACGTTGA-3′ and 5′-ATCCAGGTTACGGATATAGT-3′) and specific for FOXO1 (5′-GCTTAGAGCAGAGATGTTCTCACATT-3′, 5′-CCAGAGTCTTTGTATCAG GCAAATAA-3′, and 5′-CAAGTCCATTAATTCAGCACATTG A-3′). All procedures were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.

The Mbd2flox/flox mice were generated as described previously (18 (link)). The LyzM-Cre transgenic mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The LyzM-Cre⁺-Mbd2^flox/flox (Mbd2-CKO) mice were generated by crossing the LyzM-Cre mice with the Mbd2flox/flox mice for specific deletion of Mbd2 in macrophages, and their littermates LyzM-Cre⁻-Mbd2^flox/flox (Mbd2-C) were used as controls. Genotyping was performed using specific primers for the Cre and Mbd2^flox/flox allele (Table 2). All animal care and experimental procedures were approved by the Animal Care and Use Committee (ACUC) of Tongji Hospital and conducted in accordance with NIH guidelines (TJH-201901012).

C57BL/6, B-cell Knockout (μMT), Nur77-GFP, CD19^Cre, LyzM^Cre, Tgfb1^flox, and Tgfbr2^flox were all purchased from The Jackson Laboratory and bred for use in experiments. Studies were initiated when the mice were 6–8 weeks old. Approval for all animal experimental protocols were approved by the Institutional Animal Care and Use Committee at Northwestern University under the protocol number ISO16696. All animals were housed at the Center for Comparative Medicine at Northwestern University in a dedicated pathogen-free animal facility with 12-hour light/12-hour dark cycles and ad libitum access to food and water.